WHO Coronavirus (COVID-19) dashboard. World Health Organization. 2023. https://covid19.who.int/. Accessed 5 Apr 2023
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14:303–10.
Article PubMed PubMed Central Google Scholar
Abdelhafiz AH, Emmerton D, Sinclair AJ. Diabetes in COVID-19 pandemic-prevalence, patient characteristics and adverse outcomes. Int J Clin Pract. 2021;75:e14112.
Article CAS PubMed Google Scholar
Nassar M, Daoud A, Nso N, Medina L, Ghernautan V, Bhangoo H, et al. Diabetes mellitus and COVID-19: review article. Diabetes Metab Syndr. 2021;15:102268.
Article CAS PubMed PubMed Central Google Scholar
Wong R, Hall M, Vaddavalli R, Anand A, Arora N, Bramante CT, et al. Glycemic control and clinical outcomes in US patients with COVID-19: data from the National COVID Cohort Collaborative (N3C) database. Diabetes Care. 2022;45(5):1099–106.
Article CAS PubMed PubMed Central Google Scholar
Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, et al. New-onset diabetes in Covid-19. N Engl J Med. 2020;383:789–90.
Unnikrishnan R, Misra A. Diabetes and COVID19: a bidirectional relationship. Nutr Diabetes. 2021;11(1):21.
Article CAS PubMed PubMed Central Google Scholar
Khunti K, Del Prato S, Mathieu C, Kahn SE, Gabbay RA, Buse JB. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care. 2021;44:2645–55.
Article CAS PubMed PubMed Central Google Scholar
Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al KJ. Epidemiology of Type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10:107–11.
Article PubMed PubMed Central Google Scholar
Fignani D, Licata G, Brusco N, Nigi L, Grieco GE, Marselli L, et al. SARS-CoV-2 receptor angiotensin I-converting enzyme type 2 (ACE2) is expressed in human pancreatic β-cells and in the human pancreas microvasculature. Front Endocrinol. 2020;11:596898.
Aluganti Narasimhulu C, Singla DK. Mechanisms of COVID-19 pathogenesis in diabetes. Am J Physiol-Heart Circ Physiol. 2022;323:H403–20.
Article PubMed PubMed Central Google Scholar
Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol. 2020;18:2128-30.e2.
Article CAS PubMed PubMed Central Google Scholar
Müller JA, Groß R, Conzelmann C, Krüger J, Merle U, Steinhart J, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3:149–65.
Coate KC, Cha J, Shrestha S, Wang W, Gonçalves LM, Almaça J, et al. SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in β cells. Cell Metab. 2020;32(6):1028-1040.e4.
Article CAS PubMed PubMed Central Google Scholar
Vas P, Hopkins D, Feher M, Rubino F, B Whyte M. Diabetes, obesity and COVID-19: A complex interplay. Diabetes Obes Metab. 2020;22:1892–6.
Article CAS PubMed PubMed Central Google Scholar
Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol. 2020;16:297–8.
Article CAS PubMed PubMed Central Google Scholar
Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest. 1989;84:205–13.
Article CAS PubMed PubMed Central Google Scholar
He X, Liu C, Peng J, Li Z, Li F, Wang J, et al. COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors. Signal Transduct Target Ther. 2021;6:427.
Article CAS PubMed PubMed Central Google Scholar
Metwally AA, Mehta P, Johnson BS, Nagarjuna A, Snyder MP. COVID-19–induced new-onset diabetes: trends and technologies. Diabetes. 2021;70:2733–44.
Article CAS PubMed PubMed Central Google Scholar
Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Gilani A, et al. Hyperglycemia in acute COVID-19 is characterized by adipose tissue dysfunction and insulin resistance. Cell Metab. 2021;33(11):2174-2188.e5.
Article CAS PubMed PubMed Central Google Scholar
Chen M, Zhu B, Chen D, Hu X, Xu X, Shen W-J, et al. COVID-19 may increase the risk of insulin resistance in adult patients without diabetes: a 6-month prospective study. Endocr Pract. 2021;27:834–41.
Article PubMed PubMed Central Google Scholar
Montefusco L, Ben Nasr M, D’Addio F, Loretelli C, Rossi A, Pastore I, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3:774–85.
Article CAS PubMed PubMed Central Google Scholar
Wan L, Gao Q, Deng Y, Ke Y, Ma E, Yang H, et al. GP73 is a glucogenic hormone contributing to SARS-CoV-2-induced hyperglycemia. Nat Metab. 2022;4:29–43.
Article CAS PubMed Google Scholar
Petersen MC, Vatner DF, Shulman GI. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol. 2017;13:572–87.
Article CAS PubMed PubMed Central Google Scholar
Gerganova A, Assyov Y, Kamenov Z. Stress hyperglycemia, diabetes mellitus and COVID-19 infection: risk factors, clinical outcomes and post-discharge implications. Front Clin Diabetes Healthc. 2022;3:826006.
Article PubMed PubMed Central Google Scholar
Liu X-X, Zhu X-M, Miao Q, Ye H-Y, Zhang Z-Y, Li Y-M. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65:324–32.
Article CAS PubMed Google Scholar
Laurenzi A, Caretto A, Molinari C, Mercalli A, Melzi R, Nano R, et al. No evidence of long-term disruption of glycometabolic control after SARS-CoV-2 infection. J Clin Endocrinol Metab. 2022;107:e1009–19.
Cromer SJ, Colling C, Schatoff D, Leary M, Stamou MI, Selen DJ, et al. Newly diagnosed diabetes vs. pre-existing diabetes upon admission for COVID-19: associated factors, short-term outcomes, and long-term glycemic phenotypes. J Diabetes Complications. 2022;36:108145.
Article PubMed PubMed Central Google Scholar
Op de Beeck A, Eizirik DL. Viral infections in type 1 diabetes mellitus–why the β cells? Nat Rev Endocrinol. 2016;12:263–73.
Article CAS PubMed Google Scholar
Caruso P, Longo M, Esposito K, Maiorino MI. Type 1 diabetes triggered by covid-19 pandemic: a potential outbreak? Diabetes Res Clin Pract. 2020;164:108219.
Article CAS PubMed PubMed Central Google Scholar
Marchand L, Pecquet M, Luyton C. Type 1 diabetes onset triggered by COVID-19. Acta Diabetol. 2020;57:1265–6.
Article CAS PubMed PubMed Central Google Scholar
Genç S, Evren B, Bozbay A, Aydın EŞ, Genç Ö, Şahin I. Could COVID-19 trigger type 1 diabetes? Presentation of COVID-19 case presented with diabetic ketoacidosis. Acta Endocrinol. 2021;17:532–6.
Anindya R, Rutter GA, Meur G. New-onset type 1 diabetes and severe acute respiratory syndrome coronavirus 2 infection. Immunol Cell Biol. 2023;101:191–203.
Article CAS PubMed Google Scholar
Tison GH, Barrios J, Avram R, Kuhar P, Bostjancic B, Marcus GM, et al. Worldwide physical activity trends since COVID-19 onset. Lancet Glob Health. 2022;10:e1381–2.
Article CAS PubMed PubMed Central Google Scholar
Abed Alah M, Abdeen S, Kehyayan V, Bougmiza I. Impact of staying at home measures during COVID-19 pandemic on the lifestyle of Qatar’s population: perceived changes in diet, physical activity, and body weight. Prev Med Rep. 2021;24:101545.
Article PubMed PubMed Central Google Scholar
Lange SJ, Kompaniyets L, Freedman DS, Kraus EM, Porter R, DNP3, et al. Longitudinal trends in body mass index before and during the COVID-19 pandemic among persons aged 2–19 years - United States, 2018–2020. MMWR Morb Mortal Wkly Rep. 2021;70:1278–83.
Comments (0)